Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company to receive upfront and milestone payments, in addition to royalties
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Through the Sehat Sathi App business can access unsecured business loans at low interest
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
Board declares interim dividend of Rs 2 per equity share
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Subscribe To Our Newsletter & Stay Updated
